Jonathan L. Kaufman

Emory University — United States

Medicine · Health Sciences

58h-index16.9kcitations575works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(394), Protein Degradation and Inhibitors(156), Cancer Treatment and Pharmacology(80), Chronic Lymphocytic Leukemia Research(71), Peptidase Inhibition and Analysis(61)

Publications574 total

Supplementary Table S1 from Impaired SARS-CoV-2 Variant Neutralization and CD8<sup>+</sup> T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections
2025Open Access
Supplementary Figures from Impaired SARS-CoV-2 Variant Neutralization and CD8<sup>+</sup> T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections
2025Open Access
Supplementary Tables S2-S4 from Impaired SARS-CoV-2 Variant Neutralization and CD8<sup>+</sup> T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections
2025Open Access
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials
UNC Libraries·2025Open Access
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
UNC Libraries·2025Open Access
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
UNC Libraries·2025Open Access
Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study
Blood·2025Open Access
A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results
Blood·2025Open Access
Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression
Blood·2025Open Access
Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma
Blood·2025Open Access
Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial
Blood·2025· 1 citedOpen Access
Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance
Blood·2025Open Access
Real world evidence comparing idecabtagene vicleucel (Ide-cel, Abecma) versus ciltacabtagene autoleucel (Cilta-cel, Carvykti) chimeric antigen receptor T-cell (CART) therapy among patients with Relapsed/Refractory multiple myeloma (RRMM)
Blood·2025Open Access
Targeted deep sequencing of myeloma in a multi-institutional clinical workflow
Blood·2025Open Access
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience
Haematologica·2025· 1 citedOpen Access
The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Data in Relapsed/Refractory Multiple Myeloma in a Phase 1/2a Clinical Trial as it Advances into Cohort 7
Clinical Lymphoma Myeloma & Leukemia·2025
Optimizing the use of Chimeric Antigen Receptor T-Cell (CART) Therapy for Relapsed/Refractory Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).
Journal of Clinical Oncology·2025
Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody
Leukemia·2025Open Access
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes
Clinical Lymphoma Myeloma & Leukemia·2025
page 1 of 29Next →

Frequent Co-authors

Sagar Lonial(29), Lawrence Boise(13), Ajay K. Nooka(11), Paul G. Richardson(10), Sundar Jagannath(9), Andrzej Jakubowiak(9), Noopur Raje(8), Philippe Moreau(8), Vikas A. Gupta(8), Craig C. Hofmeister(7), Ajai Chari(7), Madhav V. Dhodapkar(7), David S. Siegel(6), Nikhil C. Munshi(6), Robert Z. Orlowski(6), Shaji Kumar(6), Kenneth C. Anderson(5), Ravi Vij(5), Robert Schlossman(5), Jesús F. San Miguel(5)